Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Recombinant/plasma-derived protein C concentrate

Protein C (Specialist drug)

Brand names: Ceprotin

Protein C concentrate is a human plasma-derived replacement therapy used in severe congenital protein C deficiency, including for purpura fulminans and warfarin-induced skin necrosis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It replaces deficient protein C, which after activation inactivates clotting factors Va and VIIIa, restoring a key natural anticoagulant pathway and reducing the prothrombotic state.

Prescribing in practice

  • Severe protein C deficiency carries a high thrombotic risk, and replacement should be co-ordinated with anticoagulation, particularly when initiating vitamin K antagonists, to avoid skin necrosis.
  • As a plasma-derived product it carries a theoretical infection-transmission risk and may cause hypersensitivity reactions.
  • It is administered intravenously by specialists with dosing guided by protein C activity levels per the SPC; paediatric use should follow a children's formulary.

Monitoring

Monitor protein C activity levels to guide dosing alongside clinical response and coagulation status.

Counselling the patient

  • Explain that this replaces a missing natural blood-thinning protein to prevent dangerous clotting.
  • Advise reporting any signs of allergic reaction during or after the infusion.

Evidence & guidelines

Use of protein C concentrate in severe congenital protein C deficiency is supported by established UK haematology practice and the SPC.

Reference: NICE; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Pathways